Myriad Builds Case For Personalized Rheumatoid Arthritis Drugs
This article was originally published in The Gray Sheet
Executive Summary
Data presented at the American College of Rheumatology meeting show that not everybody needs a biologic, and that biomarker testing could enable more cost-effective use, says Myriad subsidiary Crescendo.